180 related articles for article (PubMed ID: 1893290)
1. Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget's disease of bone: correlation with other biochemical markers of bone remodelling.
Torres R; de la Piedra C; Rapado A
Calcif Tissue Int; 1991 Jul; 49(1):14-6. PubMed ID: 1893290
[TBL] [Abstract][Full Text] [Related]
2. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
3. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
4. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
5. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
[TBL] [Abstract][Full Text] [Related]
7. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.
Delmas PD; Demiaux B; Malaval L; Chapuy MC; Meunier PJ
Calcif Tissue Int; 1986 Jan; 38(1):60-1. PubMed ID: 3079654
[TBL] [Abstract][Full Text] [Related]
8. Galactosyl hydroxylysine in assessment of Paget's bone disease.
Michalsky M; Stepan JJ; Wilczek H; Formankova J; Moro L
Clin Chim Acta; 1995 Jan; 234(1-2):101-8. PubMed ID: 7758208
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of biochemical markers of bone turnover in rats after clodronate administration.
Díaz Diego EM; de la Piedra C
Miner Electrolyte Metab; 1993; 19(6):368-72. PubMed ID: 8164618
[TBL] [Abstract][Full Text] [Related]
10. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
11. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females.
Weaver CM; Peacock M; Martin BR; McCabe GP; Zhao J; Smith DL; Wastney ME
J Bone Miner Res; 1997 Oct; 12(10):1714-20. PubMed ID: 9333133
[TBL] [Abstract][Full Text] [Related]
12. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers].
de la Piedra Gordo C; Torres Jiménez R
An Med Interna; 1990 Oct; 7(10):534-8. PubMed ID: 2104101
[TBL] [Abstract][Full Text] [Related]
14. Binding of serum osteocalcin to hydroxyapatite in Paget's disease of bone.
Torres R; de la Piedra C; Rapado A
Bone Miner; 1991 Jul; 14(1):55-65. PubMed ID: 1868269
[TBL] [Abstract][Full Text] [Related]
15. Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy.
de la Piedra C; Toural V; Rapado A
Scand J Clin Lab Invest; 1987 Oct; 47(6):587-92. PubMed ID: 3499657
[TBL] [Abstract][Full Text] [Related]
16. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers of bone turnover in Paget's disease.
Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
[TBL] [Abstract][Full Text] [Related]
18. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
[TBL] [Abstract][Full Text] [Related]
19. [Skeletal distribution and biological markers of Paget's disease].
Meunier PJ; Salson C; Delmas PD
Rev Prat; 1989 Apr; 39(13):1125-8. PubMed ID: 2786643
[TBL] [Abstract][Full Text] [Related]
20. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
